Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease

Jorge A. Zamora-Legoff, Megan L. Krause, Cynthia Crowson, Jay H Ryu, Eric Lawrence Matteson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The objective of this study is to assess the occurrence of and risk factors for serious infections in rheumatoid arthritis (RA)-associated interstitial lung disease (ILD). All patients with RA-ILD (ACR 1987 criteria for RA) seen at a single center from 1998 to 2014 were identified and manually screened for study inclusion. Follow-up data were abstracted until death or December 31, 2015. Serious infection was defined as requiring antimicrobial therapy and hospitalization. Risk of infection was analyzed by person-year (py) methods using time-dependent covariates started when the medication was first used and stopped 30 days after the medication was discontinued. Of the 181 included patients, 87 (48 %) were female. The mean age at ILD diagnosis was 67.4 (±9.9) years, and median follow-up time was 3.1 (range: 0.01 to 14.8) years. Higher infection rates were observed during the first year after ILD diagnosis (14.1 per 100 py) than subsequently (5.7 per 100 py; p = 0.001). Pneumonia was the most common (3.9 per 100 py). Overall infection risk was higher in organizing pneumonia (OP) (27.1 per 100 py) than usual interstitial pneumonia (7.7 per 100 py) or non-specific interstitial pneumonia (5.5 per 100 py) (p < 0.001). The highest infection rate observed was with a daily prednisone use >10 mg per day (15.4 per 100 py). Patients with RA-ILD are at risk of serious infection. Prednisone use >10 mg per day was associated with higher rates of infection. Immunosuppressive drug use governed by concern for risk of infection in patients with ILD resulting in channeling bias cannot be excluded.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalClinical Rheumatology
DOIs
StateAccepted/In press - Jul 22 2016

Fingerprint

Interstitial Lung Diseases
Rheumatoid Arthritis
Infection
Pneumonia
Idiopathic Pulmonary Fibrosis
Immunosuppressive Agents
Prednisone
Hospitalization
Pharmaceutical Preparations

Keywords

  • Hospitalization
  • Immunosuppression
  • Infection
  • Interstitial lung disease
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease. / Zamora-Legoff, Jorge A.; Krause, Megan L.; Crowson, Cynthia; Ryu, Jay H; Matteson, Eric Lawrence.

In: Clinical Rheumatology, 22.07.2016, p. 1-5.

Research output: Contribution to journalArticle

@article{5aea78c17aff49d0ae69d2b66601e6af,
title = "Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease",
abstract = "The objective of this study is to assess the occurrence of and risk factors for serious infections in rheumatoid arthritis (RA)-associated interstitial lung disease (ILD). All patients with RA-ILD (ACR 1987 criteria for RA) seen at a single center from 1998 to 2014 were identified and manually screened for study inclusion. Follow-up data were abstracted until death or December 31, 2015. Serious infection was defined as requiring antimicrobial therapy and hospitalization. Risk of infection was analyzed by person-year (py) methods using time-dependent covariates started when the medication was first used and stopped 30 days after the medication was discontinued. Of the 181 included patients, 87 (48 {\%}) were female. The mean age at ILD diagnosis was 67.4 (±9.9) years, and median follow-up time was 3.1 (range: 0.01 to 14.8) years. Higher infection rates were observed during the first year after ILD diagnosis (14.1 per 100 py) than subsequently (5.7 per 100 py; p = 0.001). Pneumonia was the most common (3.9 per 100 py). Overall infection risk was higher in organizing pneumonia (OP) (27.1 per 100 py) than usual interstitial pneumonia (7.7 per 100 py) or non-specific interstitial pneumonia (5.5 per 100 py) (p < 0.001). The highest infection rate observed was with a daily prednisone use >10 mg per day (15.4 per 100 py). Patients with RA-ILD are at risk of serious infection. Prednisone use >10 mg per day was associated with higher rates of infection. Immunosuppressive drug use governed by concern for risk of infection in patients with ILD resulting in channeling bias cannot be excluded.",
keywords = "Hospitalization, Immunosuppression, Infection, Interstitial lung disease, Rheumatoid arthritis",
author = "Zamora-Legoff, {Jorge A.} and Krause, {Megan L.} and Cynthia Crowson and Ryu, {Jay H} and Matteson, {Eric Lawrence}",
year = "2016",
month = "7",
day = "22",
doi = "10.1007/s10067-016-3357-z",
language = "English (US)",
pages = "1--5",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease

AU - Zamora-Legoff, Jorge A.

AU - Krause, Megan L.

AU - Crowson, Cynthia

AU - Ryu, Jay H

AU - Matteson, Eric Lawrence

PY - 2016/7/22

Y1 - 2016/7/22

N2 - The objective of this study is to assess the occurrence of and risk factors for serious infections in rheumatoid arthritis (RA)-associated interstitial lung disease (ILD). All patients with RA-ILD (ACR 1987 criteria for RA) seen at a single center from 1998 to 2014 were identified and manually screened for study inclusion. Follow-up data were abstracted until death or December 31, 2015. Serious infection was defined as requiring antimicrobial therapy and hospitalization. Risk of infection was analyzed by person-year (py) methods using time-dependent covariates started when the medication was first used and stopped 30 days after the medication was discontinued. Of the 181 included patients, 87 (48 %) were female. The mean age at ILD diagnosis was 67.4 (±9.9) years, and median follow-up time was 3.1 (range: 0.01 to 14.8) years. Higher infection rates were observed during the first year after ILD diagnosis (14.1 per 100 py) than subsequently (5.7 per 100 py; p = 0.001). Pneumonia was the most common (3.9 per 100 py). Overall infection risk was higher in organizing pneumonia (OP) (27.1 per 100 py) than usual interstitial pneumonia (7.7 per 100 py) or non-specific interstitial pneumonia (5.5 per 100 py) (p < 0.001). The highest infection rate observed was with a daily prednisone use >10 mg per day (15.4 per 100 py). Patients with RA-ILD are at risk of serious infection. Prednisone use >10 mg per day was associated with higher rates of infection. Immunosuppressive drug use governed by concern for risk of infection in patients with ILD resulting in channeling bias cannot be excluded.

AB - The objective of this study is to assess the occurrence of and risk factors for serious infections in rheumatoid arthritis (RA)-associated interstitial lung disease (ILD). All patients with RA-ILD (ACR 1987 criteria for RA) seen at a single center from 1998 to 2014 were identified and manually screened for study inclusion. Follow-up data were abstracted until death or December 31, 2015. Serious infection was defined as requiring antimicrobial therapy and hospitalization. Risk of infection was analyzed by person-year (py) methods using time-dependent covariates started when the medication was first used and stopped 30 days after the medication was discontinued. Of the 181 included patients, 87 (48 %) were female. The mean age at ILD diagnosis was 67.4 (±9.9) years, and median follow-up time was 3.1 (range: 0.01 to 14.8) years. Higher infection rates were observed during the first year after ILD diagnosis (14.1 per 100 py) than subsequently (5.7 per 100 py; p = 0.001). Pneumonia was the most common (3.9 per 100 py). Overall infection risk was higher in organizing pneumonia (OP) (27.1 per 100 py) than usual interstitial pneumonia (7.7 per 100 py) or non-specific interstitial pneumonia (5.5 per 100 py) (p < 0.001). The highest infection rate observed was with a daily prednisone use >10 mg per day (15.4 per 100 py). Patients with RA-ILD are at risk of serious infection. Prednisone use >10 mg per day was associated with higher rates of infection. Immunosuppressive drug use governed by concern for risk of infection in patients with ILD resulting in channeling bias cannot be excluded.

KW - Hospitalization

KW - Immunosuppression

KW - Infection

KW - Interstitial lung disease

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84979248233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979248233&partnerID=8YFLogxK

U2 - 10.1007/s10067-016-3357-z

DO - 10.1007/s10067-016-3357-z

M3 - Article

C2 - 27448151

AN - SCOPUS:84979248233

SP - 1

EP - 5

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -